Search reports.
Intravenous Iron Drugs Market Share & Growth | Forecast 2031
Get free sample report Request for Customiztion Buy Now

Intravenous Iron Drugs Market Share & Growth | Forecast 2031

Segments - Intravenous Iron Drugs Market by Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-710 | 4.6 Rating | 79 Reviews | 132 Pages | Format : PDF Excel PPT

Report Description


Intravenous Iron Drugs Market Outlook 2031:

The global intravenous iron drugs market size was valued at USD 2.92 Billion in 2022 and is projected to reach USD 6.14 Billion by 2031, expanding at a CAGR of 8.6% during the forecast period 2023 - 2031. The growth of the market is attributed to the increasing geriatric population, increasing people with chronic diseases and patients undergoing dialysis.

Iron is a crucial mineral of the body. It is a critical element of hemoglobin which delivers oxygen throughout your body. Iron is also required for heme synthesis, energy metabolism, neurotransmitter creation, myoglobin development, collagen development, and immune system function.

Intravenous Iron Drugs Market Outlook

Iron deficiency is one of the leading causes of iron deficiency anemia (IDA), which is linked to an increased risk of morbidity and death. Oral and intravenous iron supplements are available. Oral iron supplements are slower to intravenous iron preparations because they result in a greater and faster increase in iron and hemoglobin levels.

Gastrointestinal side effects, low adherence, low gastrointestinal absorption, and noncompliance are among drawbacks of oral supplements.

Intravenous iron infusion is a method of delivering iron to your blood rapidly by inserting a tiny tube into a vein in your arm and administering a liquid solution containing iron. Doctors typically prescribe iron infusions to treat iron deficiency anemia. Dietary modifications and iron supplementation in tablet form are usually used to treat iron deficiency anemia.

Doctors may, however, suggest iron infusions in specific circumstances. The demand for iron in a pregnant woman increases as her fetus grows. The mother's iron levels may decline as the fetus takes iron from her body, leading in anemia. As a result, doctors occasionally prescribe iron infusions for pregnant women. An iron infusion is a rapid technique to boost your body's iron levels.

It is a faster solution than supplements or dietary adjustments. This can be extremely beneficial in cases of severe anemia. An iron infusion has physical benefits such as increased energy and better breathing. These advantages should begin to manifest a few weeks following your final infusion therapy. The amount of time these advantages persist is determined on the cause of your iron deficiency anemia and if any additional treatments are taken to raise your iron levels.

For example, regular blood loss, such as through menstruation, can result in a continual reduction in iron levels. The effects of an iron infusion might last anywhere from a few months to a few years, depending on condition. Additional iron-increasing treatments, like as supplementation and dietary adjustments, may be recommended by your doctor to extend the effects.

  • Increasing incidence of iron deficiency, growing chronic kidney disorders patients undergoing dialysis and increasing diabetic patients around the world are factors driving the market growth during the forecast period.
  • Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology conditions, and accurate, quick, and convenient access to IV iron doses are projected to boost the market growth during the forecast period.
  • Increased initiatives by public and private institutes for spreading the awareness regarding the need for safe levels of iron in pregnant women is expected to fuel the market growth in the coming years.
  • Growing awareness among the people regarding healthcare and personal care is estimated to boost the market growth during the forecast period.
  • Stringent drug approval framework is projected to hamper the market growth during the forecast period.
  • Side-effects associated with intravenous iron infusion is anticipated to impede the market growth during the forecast period.
  • High cost of treatment and not suitable for first trimester of pregnancy are major challenges that can restrict the market growth during the forecast period.
  • Increased emphasis on R&D for novel product development and increasing need for preventing anemia in pregnant women are expected to offer lucrative opportunities for the market players.

Scope of the Intravenous Iron Drugs Market Report

The report on the global intravenous iron drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Intravenous Iron Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Allergan, Inc.; Daiichi Sankyo Company, Ltd.; Rockwell Medical Technologies, Inc.; AMAG Pharmaceuticals. Inc.; Sanofi; Fresenius Medical Care AG & Co.; Vifor Pharma Management Ltd.; Pharmacosmos A/S; Shield Therapeutics Plc; American Regent. Inc.

Intravenous Iron Drugs Market Segment Insights

Ferric carboxymaltose segment is expected to account for a key share of the market

Based on product, the intravenous iron drugs market is segmented into iron dextran, iron sucrose, ferric carboxymaltose, and others. The ferric carboxymaltose segment is expected to account for a key share of the market during the forecast period due to increasing use in drug development, improved performance, and lower cost.

On the other hand, the iron sucrose segment is anticipated to expand at a rapid pace during the forecast period due to increased number of product launches such as diafer and feraccru.

Intravenous Iron Drugs Market Products

Chronic kidney disease segment is expected to constitute a key share of the market

Based on application, the intravenous iron drugs market is segmented into chronic kidney disease, inflammatory bowel disease, cancer, and other. The chronic kidney disease segment is expected to constitute a key share of the market during the forecast period due to increasing incidence, a growing geriatric population, and a shift towards a sedentary lifestyle.

Intravenous medicines are preferred over oral tablets in several situations of iron deficiency. These IV iron drugs are used when the body cannot absorb dietary iron, when a quick rise in hemoglobin is required, or when there is underlying inflammation, such as in inflammatory bowel disease or Chronic Kidney Disorder patients.

On the other hand, the cancer segment is anticipated to expand at a rapid pace during the forecast period owing to its increasing prevalence and increasing oncology cohort.

Intravenous Iron Drugs Market Application

North America is anticipated to dominate the market

On the basis of regions, the intravenous iron drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period.

The regional market growth can be attributed to increasing use of intravenous iron medications in cancer research, the use of low-cost & compact intravenous iron medications in clinical diagnostics, and the development of research lab infrastructure.

On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increasing government investment in the biotechnology and biopharmaceutical industries, the development of innovative biologics, vaccines, and medications, the expansion of medical treatment for infectious and chronic illnesses, and a large number of investment possibilities in these markets. The growth of the region can be highly attributed to countries such as Japan, China, South Korea, and India.

Intravenous Iron Drugs Market Region

Segments

The global intravenous iron drugs market has been segmented on the basis of

Product

  • Iron Dextran
  • Iron Sucrose
  • Ferric Carboxymaltose
  • Others

Application

  • Chronic Kidney Disease
  • Inflammatory Bowel Disease
  • Cancer
  • Other Diseases

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Allergan, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Rockwell Medical Technologies, Inc.
  • AMAG Pharmaceuticals. Inc.
  • Sanofi
  • Fresenius Medical Care AG & Co.
  • Vifor Pharma Management Ltd.
  • Pharmacosmos A/S
  • Shield Therapeutics Plc.
  • American Regent. Inc.

Competitive Landscape

Key players competing in the intravenous iron drugs market are Allergan, Inc.; Daiichi Sankyo Company, Ltd.; Rockwell Medical Technologies, Inc.; AMAG Pharmaceuticals. Inc.; Sanofi; Fresenius Medical Care AG & Co.; Vifor Pharma Management Ltd.; Pharmacosmos A/S; Shield Therapeutics Plc; American Regent. Inc.

Emergence of new entrants and the existence of well-established companies, the global intravenous iron drugs market is extremely competitive. Some of the key business strategies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase companies market shares.

Intravenous Iron Drugs Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Intravenous Iron Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Intravenous Iron Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Intravenous Iron Drugs Market - Supply Chain
  4.5. Global Intravenous Iron Drugs Market Forecast
     4.5.1. Intravenous Iron Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Intravenous Iron Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Intravenous Iron Drugs Market Absolute $ Opportunity
5. Global Intravenous Iron Drugs Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Intravenous Iron Drugs Market Size and Volume Forecast by Types
     5.3.1. Iron Dextran
     5.3.2. Iron Sucrose
     5.3.3. Ferric Carboxymaltose
     5.3.4. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Intravenous Iron Drugs Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     6.3.1. Chronic Kidney Disease
     6.3.2. Inflammatory Bowel Disease
     6.3.3. Cancer
     6.3.4. Other Diseases
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Intravenous Iron Drugs Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Intravenous Iron Drugs Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Intravenous Iron Drugs Demand Share Forecast, 2019-2026
8. North America Intravenous Iron Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Intravenous Iron Drugs Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Intravenous Iron Drugs Market Size and Volume Forecast by Types
     8.4.1. Iron Dextran
     8.4.2. Iron Sucrose
     8.4.3. Ferric Carboxymaltose
     8.4.4. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     8.7.1. Chronic Kidney Disease
     8.7.2. Inflammatory Bowel Disease
     8.7.3. Cancer
     8.7.4. Other Diseases
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
9. Latin America Intravenous Iron Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Types
     9.4.1. Iron Dextran
     9.4.2. Iron Sucrose
     9.4.3. Ferric Carboxymaltose
     9.4.4. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     9.7.1. Chronic Kidney Disease
     9.7.2. Inflammatory Bowel Disease
     9.7.3. Cancer
     9.7.4. Other Diseases
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Intravenous Iron Drugs Demand Share Forecast, 2019-2026
10. Europe Intravenous Iron Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Types
     10.4.1. Iron Dextran
     10.4.2. Iron Sucrose
     10.4.3. Ferric Carboxymaltose
     10.4.4. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     10.7.1. Chronic Kidney Disease
     10.7.2. Inflammatory Bowel Disease
     10.7.3. Cancer
     10.7.4. Other Diseases
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Intravenous Iron Drugs Demand Share Forecast, 2019-2026
11. Asia Pacific Intravenous Iron Drugs Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Types
     11.4.1. Iron Dextran
     11.4.2. Iron Sucrose
     11.4.3. Ferric Carboxymaltose
     11.4.4. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     11.7.1. Chronic Kidney Disease
     11.7.2. Inflammatory Bowel Disease
     11.7.3. Cancer
     11.7.4. Other Diseases
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Intravenous Iron Drugs Demand Share Forecast, 2019-2026
12. Middle East & Africa Intravenous Iron Drugs Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Types
     12.4.1. Iron Dextran
     12.4.2. Iron Sucrose
     12.4.3. Ferric Carboxymaltose
     12.4.4. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Intravenous Iron Drugs Market Size and Volume Forecast by Applications
     12.7.1. Chronic Kidney Disease
     12.7.2. Inflammatory Bowel Disease
     12.7.3. Cancer
     12.7.4. Other Diseases
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Intravenous Iron Drugs Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Intravenous Iron Drugs Market: Market Share Analysis
  13.2. Intravenous Iron Drugs Distributors and Customers
  13.3. Intravenous Iron Drugs Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Allergan, Inc.
     13.4.2. Daiichi Sankyo Company, Ltd.
     13.4.3. Rockwell Medical Technologies, Inc.
     13.4.4. AMAG Pharmaceuticals. Inc.
     13.4.5. Sanofi
     13.4.6. Fresenius Medical Care AG & Co.
     13.4.7. Vifor Pharma Management Ltd.

Methodology

Our Clients

Dassault Aviation
Nestle SA
sinopec
The John Holland Group
General Electric
Microsoft
Siemens Healthcare
General Mills